行情

RIGL

RIGL

里格尔制药
NASDAQ

实时行情|Nasdaq Last Sale

1.570
-0.030
-1.88%
已收盘, 17:29 03/27 EDT
开盘
1.550
昨收
1.600
最高
1.635
最低
1.440
成交量
132.33万
成交额
--
52周最高
3.100
52周最低
1.230
市值
2.65亿
市盈率(TTM)
-3.9279
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测RIGL价格均价为7.43,最高价位9.00,最低价为5.00。

EPS

RIGL 新闻

更多
  • Edited Transcript of RIGL earnings conference call or presentation 27-Feb-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 6天前
  • The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
  • Benzinga · 03/13 11:52
  • Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) A Volatile Stock?
  • Simply Wall St. · 03/12 16:02
  • Rigel Pharmaceuticals Continues To Grow While The Stock Remains Subdued
  • Seeking Alpha - Article · 03/03 18:40

所属板块

生物技术和医学研究
-2.43%
制药与医学研究
-0.87%

热门股票

代码
价格
涨跌幅

RIGL 简况

Rigel Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s research focuses on signaling pathways that are critical to disease mechanisms. The Company’s product include TAVALISSE is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase I study for its interleukin receptor associated kinase (IRAK) program. In addition, it has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics.
展开

微牛提供Rigel Pharmaceuticals, Inc.(NASDAQ-RIGL)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的RIGL股票新闻,以帮助您做出投资决策。